Src Points the Way to Biomarkers and Chemotherapeutic Targets

Genes and Cancer

Volumn 3, Issue 5-6, 2012, Pages 426-435

  Krishnan, Harini ^a   Miller, W Todd ^b   Goldberg, Gary S ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Abl; cancer; Cas; connexins; contact normalization; kinase; pdpn; src

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CRK ASSOCIATED SUBSTRATE PROTEIN; FIBRONECTIN; LAMININ; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; NEURAL WISKOTT ALDRICH SYNDROME PROTEIN; PODOPLANIN; PROTEIN SH2; PROTEIN SH3; PROTEIN TYROSINE KINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SLIT2 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SUNITINIB; VASCULOTROPIN RECEPTOR 2; VITRONECTIN;

ARTICLE; ASTROCYTOMA; BRAIN CANCER; BREAST CANCER; BREAST CARCINOMA; CARCINOGENESIS; CELL CONTACT; CELL MIGRATION; DRUG TARGETING; ENZYME STRUCTURE; GENE EXPRESSION; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG METASTASIS; MALIGNANT TRANSFORMATION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR SUPPRESSOR GENE;

EID: 84875507436     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912458583     Document Type: Article

References (168)

1. Rous P.A sarcoma of the fowl transmissible by an agent separable from the tumor cells.J Exp Med. 1911;13:397-411.
2. Rous P,Murphy JB.On the causation by filterable agents of three distinct chicken tumors.J Exp Med. 1914;19:52-68.
3. Duesberg PH,Vogt PK.Differences between the ribonucleic acids of transforming and nontransforming avian tumor viruses.Proc Natl Acad Sci U S A. 1970;67:1673-80.
4. Wang LH,Duesberg PH,Kawai S,Hanafusa H.Location of envelope-specific and sarcoma-specific oligonucleotides on RNA of Schmidt-Ruppin Rous sarcoma virus.Proc Natl Acad Sci U S A. 1976;73:447-51.
5. Martin GS.The hunting of the Src.Nat Rev Mol Cell Biol. 2001;2:467-75.
6. Czernilofsky AP,DeLorbe W,Swanstrom R, et al.The nucleotide sequence of an untranslated but conserved domain at the 3′ end of the avian sarcoma virus genome. Nucleic Acids Res. 1980;8:2967-84.
7. Takeya T,Hanafusa H.DNA sequence of the viral and cellular src gene of chickens, II: comparison of the src genes of two strains of avian sarcoma virus and of the cellular homolog.J Virol. 1982;44:12-8.
8. Schwartz DE,Tizard R,Gilbert W.Nucleotide sequence of Rous sarcoma virus.Cell. 1983;32:853-69.
9. Huebner RJ,Todaro GJ.Oncogenes of RNA tumor viruses as determinants of cancer.Proc Natl Acad Sci U S A. 1969;64:1087-94.
10. Martin GS.The road to Src.Oncogene. 2004;23:7910-7.
11. Stehelin D,Guntaka RV,Varmus HE,Bishop JM.Purification of DNA complementary to nucleotide sequences required for neoplastic transformation of fibroblasts by avian sarcoma viruses.J Mol Biol. 1976;101:349-65.
12. Stehelin D,Varmus HE,Bishop JM,Vogt PK.DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA.Nature. 1976;260:170-3.
13. Shalloway D,Zelenetz AD,Cooper GM.Molecular cloning and characterization of the chicken gene homologous to the transforming gene of Rous sarcoma virus.Cell. 1981;24:531-41.
14. Takeya T,Hanafusa H.Structure and sequence of the cellular gene homologous to the RSV src gene and the mechanism for generating the transforming virus.Cell. 1983;32:881-90.
15. Parker RC,Varmus HE,Bishop JM.Expression of v-src and chicken c-src in rat cells demonstrates qualitative differences between pp60v-src and pp60c-src.Cell. 1984;37:131-9.
16. Collett MS,Erikson RL.Protein kinase activity associated with the avian sarcoma virus src gene product.Proc Natl Acad Sci U S A. 1978;75:2021-4.
17. Brugge J,Erikson E,Collett MS,Erikson RI.Peptide analysis of the transformation-specific antigen from avian sarcoma virus-transformed cells.J Virol. 1978;26:773-82.
18. Levinson AD,Oppermann H,Levintow L,Varmus HE,Bishop JM.Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein.Cell. 1978;15:561-72.
19. Hunter T,Sefton BM.Transforming gene product of Rous sarcoma virus phosphorylates tyrosine.Proc Natl Acad Sci U S A. 1980;77:1311-5.
20. Yeatman TJ.A renaissance for SRC.Nat Rev Cancer. 2004;4:470-80.
21. Guarino M.Src signaling in cancer invasion.J Cell Physiol. 2010;223:14-26.
22. Erpel T,Courtneidge SA.Src family protein tyrosine kinases and cellular signal transduction pathways.Curr Opin Cell Biol. 1995;7:176-82.
23. Thomas SM,Brugge JS.Cellular functions regulated by Src family kinases.Annu Rev Cell Dev Biol. 1997;13:513-609.
24. Parsons SJ,Parsons JT.Src family kinases, key regulators of signal transduction.Oncogene. 2004;23:7906-9.
25. Frame MC.Src in cancer: deregulation and consequences for cell behaviour.Biochim Biophys Acta. 2002;1602:114-30.
26. Mayer BJ.SH3 domains: complexity in moderation.J Cell Sci. 2001;114:1253-63.
27. Schlessinger J,Lemmon MA.SH2 and PTB domains in tyrosine kinase signaling.Sci STKE. 2003;2003:RE12.
28. Pawson T.Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems.Cell. 2004;116:191-203.
29. Erpel T,Superti-Furga G,Courtneidge SA.Mutational analysis of the Src SH3 domain: the same residues of the ligand binding surface are important for intra- and intermolecular interactions.Embo J. 1995;14:963-75.
30. Bjorge JD,Jakymiw A,Fujita DJ.Selected glimpses into the activation and function of Src kinase.Oncogene. 2000;19:5620-35.
31. Irby RB,Yeatman TJ.Role of Src expression and activation in human cancer.Oncogene. 2000;19:5636-42.
32. Ishizawar R,Parsons SJ.c-Src and cooperating partners in human cancer.Cancer Cell. 2004;6:209-14.
33. Shah AN,Gallick GE.Src, chemoresistance and epithelial to mesenchymal transition: are they related?.Anticancer Drugs. 2007;18:371-5.
34. Kim MP,Park SI,Kopetz S,Gallick GE.Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis.Cell Tissue Res. 2009;335:249-59.
35. Aleshin A,Finn RS.SRC: a century of science brought to the clinic.Neoplasia. 2010;12:599-607.
36. Sen B,Johnson FM.Regulation of SRC family kinases in human cancers.J Signal Transduct. 2011;2011:865819.
37. Reynolds AB,Kanner SB,Wang HC,Parsons JT.Stable association of activated pp60src with two tyrosine-phosphorylated cellular proteins.Mol Cell Biol. 1989;9:3951-8.
38. Matsuda M,Mayer BJ,Fukui Y,Hanafusa H.Binding of transforming protein, P47gag-crk, to a broad range of phosphotyrosine-containing proteins.Science. 1990;248:1537-9.
39. Mayer BJ,Hanafusa H.Association of the v-crk oncogene product with phosphotyrosine-containing proteins and protein kinase activity.Proc Natl Acad Sci U S A. 1990;87:2638-42.
40. Goldberg GS,Alexander DB,Pellicena P,Zhang ZY,Tsuda H,Miller WT.Src phosphorylates Cas on tyrosine 253 to promote migration of transformed cells.J Biol Chem. 2003;278:46533-40.
41. Shen Y,Jia Z,Nagele RG,Ichikawa H,Goldberg GS.SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells.Cancer Res. 2006;66:1543-52.
42. Sakai R,Iwamatsu A,Hirano N, et al.A novel signaling molecule, p130, forms stable complexes in vivo with v- Crk and v-Src in a tyrosine phosphorylation-dependent manner.Embo J. 1994;13:3748-56.
43. Bouton AH,Riggins RB,Bruce-Staskal PJ.Functions of the adapter protein Cas: signal convergence and the determination of cellular responses.Oncogene. 2001;20:6448-58.
44. Tikhmyanova N,Little JL,Golemis EA.CAS proteins in normal and pathological cell growth control.Cell Mol Life Sci. 2010;67:1025-48.
45. Polte TR,Hanks SK.Interaction between focal adhesion kinase and Crk-associated tyrosine kinase substrate p130Cas.Proc Natl Acad Sci U S A. 1995;92:10678-82.
46. Harte MT,Hildebrand JD,Burnham MR,Bouton AH,Parsons JT.p130Cas, a substrate associated with v-Src and v-Crk, localizes to focal adhesions and binds to focal adhesion kinase.J Biol Chem. 1996;271:13649-55.
47. Garcia-Guzman M,Dolfi F,Russello M,Vuori K.Cell adhesion regulates the interaction between the docking protein p130(Cas) and the 14-3-3 proteins.J Biol Chem. 1999;274:5762-8.
48. Briknarova K,Nasertorabi F,Havert ML, et al.The serine-rich domain from Crk-associated substrate (p130cas) is a four-helix bundle.J Biol Chem. 2005;280:21908-14.
49. Nakamoto T,Sakai R,Ozawa K,Yazaki Y,Hirai H.Direct binding of C-terminal region of p130Cas to SH2 and SH3 domains of Src kinase.J Biol Chem. 1996;271:8959-65.
50. Burnham MR,Bruce-Staskal PJ,Harte MT, et al.Regulation of c-SRC activity and function by the adapter protein CAS.Mol Cell Biol. 2000;20:5865-78.
51. Ruest PJ,Shin NY,Polte TR,Zhang X,Hanks SK.Mechanisms of CAS substrate domain tyrosine phosphorylation by FAK and Src.Mol Cell Biol. 2001;21:7641-52.
52. Pellicena P,Miller WT.Processive phosphorylation of p130Cas by Src depends on SH3-polyproline interactions.J Biol Chem. 2001;276:28190-6.
53. Chodniewicz D,Klemke RL.Regulation of integrin-mediated cellular responses through assembly of a CAS/Crk scaffold.Biochim Biophys Acta. 2004;1692:63-76.
54. Defilippi P,Di Stefano P,Cabodi S.p130Cas: a versatile scaffold in signaling networks.Trends Cell Biol. 2006;16:257-63.
55. Petruzzelli L,Takami M,Herrera R.Adhesion through the interaction of lymphocyte function-associated antigen-1 with intracellular adhesion molecule-1 induces tyrosine phosphorylation of p130cas and its association with c-CrkII.J Biol Chem. 1996;271:7796-801.
56. Ojaniemi M,Vuori K.Epidermal growth factor modulates tyrosine phosphorylation of p130Cas: involvement of phosphatidylinositol 3′-kinase and actin cytoskeleton.J Biol Chem. 1997;272:25993-8.
57. Nakamura I,Jimi E,Duong LT, et al.Tyrosine phosphorylation of p130Cas is involved in actin organization in osteoclasts.J Biol Chem. 1998;273:11144-9.
58. O'Neill GM,Fashena SJ,Golemis EA.Integrin signalling: a new Cas(t) of characters enters the stage.Trends Cell Biol. 2000;10:111-9.
59. Honda H,Oda H,Nakamoto T, et al.Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas.Nat Genet. 1998;19:361-5.
60. Honda H,Nakamoto T,Sakai R,Hirai H.p130(Cas), an assembling molecule of actin filaments, promotes cell movement, cell migration, and cell spreading in fibroblasts.Biochem Biophys Res Commun. 1999;262:25-30.
61. Nakamoto T,Sakai R,Honda H, et al.Requirements for localization of p130cas to focal adhesions.Mol Cell Biol. 1997;17:3884-97.
62. Vuori K,Ruoslahti E.Tyrosine phosphorylation of p130Cas and cortactin accompanies integrin-mediated cell adhesion to extracellular matrix.J Biol Chem. 1995;270:22259-62.
63. Songyang Z,Shoelson SE,Chaudhuri M, et al.SH2 domains recognize specific phosphopeptide sequences.Cell. 1993;72:767-78.
64. Klemke RL,Leng J,Molander R,Brooks PC,Vuori K,Cheresh DA.CAS/Crk coupling serves as a "molecular switch" for induction of cell migration.J Cell Biol. 1998;140:961-72.
65. Garton AJ,Tonks NK.Regulation of fibroblast motility by the protein tyrosine phosphatase PTP-PEST.J Biol Chem. 1999;274:3811-8.
66. Kain KH,Klemke RL.Inhibition of cell migration by Abl family tyrosine kinases through uncoupling of Crk-CAS complexes.J Biol Chem. 2001;276:16185-92.
67. Kiyokawa E,Hashimoto Y,Kurata T,Sugimura H,Matsuda M.Evidence that DOCK180 up-regulates signals from the CrkII-p130(Cas) complex.J Biol Chem. 1998;273:24479-84.
68. Arai A,Nosaka Y,Kohsaka H,Miyasaka N,Miura O.CrkL activates integrin-mediated hematopoietic cell adhesion through the guanine nucleotide exchange factor C3G.Blood. 1999;93:3713-22.
69. Cho SY,Klemke RL.Extracellular-regulated kinase activation and CAS/Crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix.J Cell Biol. 2000;149:223-36.
70. Huang J,Hamasaki H,Nakamoto T, et al.Differential regulation of cell migration, actin stress fiber organization, and cell transformation by functional domains of Crk-associated substrate.J Biol Chem. 2002;277:27265-72.
71. Shin NY,Dise RS,Schneider-Mergener J,Ritchie MD,Kilkenny DM,Hanks SK.Subsets of the major tyrosine phosphorylation sites in Crk-associated substrate (CAS) are sufficient to promote cell migration.J Biol Chem. 2004;279:38331-7.
72. Patwardhan P,Shen Y,Goldberg GS,Miller WT.Individual Cas phosphorylation sites are dispensable for processive phosphorylation by Src and anchorage-independent cell growth.J Biol Chem. 2006;281:20689-97.
73. Brabek J,Constancio SS,Siesser PF,Shin NY,Pozzi A,Hanks SK.Crk-associated substrate tyrosine phosphorylation sites are critical for invasion and metastasis of SRC-transformed cells.Mol Cancer Res. 2005;3:307-15.
74. Plattner R,Kadlec L,DeMali KA,Kazlauskas A,Pendergast AM.c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF.Genes Dev. 1999;13:2400-11.
75. Khusial PR,Vadla B,Krishnan H, et al.Src activates Abl to augment Robo1 expression in order to promote tumor cell migration.Oncotarget. 2010;1:198-209.
76. Lin J,Arlinghaus R.Activated c-Abl tyrosine kinase in malignant solid tumors.Oncogene. 2008;27:4385-91.
77. Johnson FM,Saigal B,Talpaz M,Donato NJ.Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.Clin Cancer Res. 2005;11:6924-32.
78. Nam S,Kim D,Cheng JQ, et al.Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.Cancer Res. 2005;65:9185-9.
79. Azam M,Nardi V,Shakespeare WC, et al.Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.Proc Natl Acad Sci U S A. 2006;103:9244-9.
80. Jallal H,Valentino ML,Chen G,Boschelli F,Ali S,Rabbani SA.A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.Cancer Res. 2007;67:1580-8.
81. Ingley E.Src family kinases: regulation of their activities, levels and identification of new pathways.Biochim Biophys Acta. 2008;1784:56-65.
82. Levinson NM,Kuchment O,Shen K, et al.A Src-like inactive conformation in the abl tyrosine kinase domain.PLoS Biol. 2006;4:e144.
83. Srinivasan D,Plattner R.Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells.Cancer Res. 2006;66:5648-55.
84. Wen ST,Jackson PK,Van Etten RA.The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products.Embo J. 1996;15:1583-95.
85. Hernandez SE,Krishnaswami M,Miller AL,Koleske AJ.How do Abl family kinases regulate cell shape and movement?.Trends Cell Biol. 2004;14:36-44.
86. Suzuki J,Shishido T.Regulation of cellular transformation by oncogenic and normal Abl kinases.J Biochem. 2007;141:453-8.
87. Van Etten RA.Cycling, stressed-out and nervous: cellular functions of c-Abl.Trends Cell Biol. 1999;9:179-86.
88. Van Etten RA,Jackson PK,Baltimore D,Sanders MC,Matsudaira PT,Janmey PA.The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity.J Cell Biol. 1994;124:325-40.
89. Wong K,Ren XR,Huang YZ, et al.Signal transduction in neuronal migration: roles of GTPase activating proteins and the small GTPase Cdc42 in the Slit-Robo pathway.Cell. 2001;107:209-21.
90. Alexander DB,Ichikawa H,Bechberger JF, et al.Normal cells control the growth of neighboring transformed cells independent of gap junctional communication and SRC activity.Cancer Res. 2004;64:1347-58.
91. Pahujaa M,Anikin M,Goldberg GS.Phosphorylation of connexin43 induced by Src: regulation of gap junctional communication between transformed cells.Exp Cell Res. 2007;313:4083-90.
92. Wang B,Xiao Y,Ding BB, et al.Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity.Cancer Cell. 2003;4:19-29.
93. Fujiwara M,Ghazizadeh M,Kawanami O.Potential role of the Slit/Robo signal pathway in angiogenesis.Vasc Med. 2006;11:115-21.
94. Zallen JA,Yi BA,Bargmann CI.The conserved immunoglobulin superfamily member SAX-3/Robo directs multiple aspects of axon guidance in C. elegans.Cell. 1998;92:217-27.
95. Legg JA,Herbert JM,Clissold P,Bicknell R.Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration.Angiogenesis. 2008;11:13-21.
96. Minn AJ,Gupta GP,Siegel PM, et al.Genes that mediate breast cancer metastasis to lung.Nature. 2005;436:518-24.
97. Ito H,Funahashi S,Yamauchi N, et al.Identification of ROBO1 as a novel hepatocellular carcinoma antigen and a potential therapeutic and diagnostic target.Clin Cancer Res. 2006;12:3257-64.
98. Schmid BC,Rezniczek GA,Fabjani G,Yoneda T,Leodolter S,Zeillinger R.The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells.Breast Cancer Res Treat. 2007;106:333-42.
99. Mertsch S,Schmitz N,Jeibmann A,Geng JG,Paulus W,Senner V.Slit2 involvement in glioma cell migration is mediated by Robo1 receptor.J Neurooncol. 2008;87:1-7.
100. Yamazaki D,Kurisu S,Takenawa T.Regulation of cancer cell motility through actin reorganization.Cancer Sci. 2005;96:379-86.
101. Fernando HS,Kynaston HG,Jiang WG.WASP and WAVE proteins: vital intrinsic regulators of cell motility and their role in cancer [review].Int J Mol Med. 2009;23:141-8.
102. Millard TH,Sharp SJ,Machesky LM.Signalling to actin assembly via the WASP (Wiskott-Aldrich syndrome protein)-family proteins and the Arp2/3 complex.Biochem J. 2004;380:1-17.
103. Jaffe AB,Hall A.Rho GTPases: biochemistry and biology.Annu Rev Cell Dev Biol. 2005;21:247-69.
104. Aspenstrom P,Fransson A,Saras J.Rho GTPases have diverse effects on the organization of the actin filament system.Biochem J. 2004;377:327-37.
105. Etienne-Manneville S,Hall A.Rho GTPases in cell biology.Nature. 2002;420:629-35.
106. Rubin H.Contact interactions between cells that suppress neoplastic development: can they also explain metastatic dormancy?.Adv Cancer Res. 2008;100:159-202.
107. Ochoa-Alvarez JA,George C,Krishnan H,Wu X,Goldberg GSIn: Extracellular and intracellular signaling. London: RSC Publishing; 2011:105-15.
108. Rubin H.The suppression of morphological alterations in cells infected with Rous sarcoma virus.Virology. 1960;12:14-31.
109. Stoker MG,Shearer M,O'Neill C.Growth inhibition of polyoma-transformed cells by contact with static normal fibroblasts.J Cell Sci. 1966;1:297-310.
110. Nelson MA,Futscher BW,Kinsella T,Wymer J,Bowden GT.Detection of mutant Ha-ras genes in chemically initiated mouse skin epidermis before the development of benign tumors.Proc Natl Acad Sci U S A. 1992;89:6398-402.
111. Holst CR,Nuovo GJ,Esteller M, et al.Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia.Cancer Res. 2003;63:1596-601.
112. Enomoto T,Yamasaki H.Phorbol ester-mediated inhibition of intercellular communication in BALB/c 3T3 cells: relationship to enhancement of cell transformation.Cancer Res. 1985;45:2681-8.
113. Stoker MG.Transfer of growth inhibition between normal and virus-transformed cells: autoradiographic studies using marked cells.J Cell Sci. 1967;2:293-304.
114. La Rocca SA,Grossi M,Falcone G,Alema S,Tato F.Interaction with normal cells suppresses the transformed phenotype of v-myc- transformed quail muscle cells.Cell. 1989;58:123-31.
115. Matsuyoshi N,Hamaguchi M,Taniguchi S,Nagafuchi A,Tsukita S,Takeichi M.Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phosphorylation in metastatic fibroblasts.J Cell Biol. 1992;118:703-14.
116. Behrens J,Vakaet L,Friis R, et al.Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene.J Cell Biol. 1993;120:757-66.
117. Hamaguchi M,Matsuyoshi N,Ohnishi Y,Gotoh B,Takeichi M,Nagai Y.p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system.Embo J. 1993;12:307-14.
118. Thiery JP.Epithelial-mesenchymal transitions in tumour progression.Nat Rev Cancer. 2002;2:442-54.
119. Lampe PD,Lau AF.The effects of connexin phosphorylation on gap junctional communication.Int J Biochem Cell Biol. 2004;36:1171-86.
120. Naus CC.Gap junctions and tumour progression.Can J Physiol Pharmacol. 2002;80:136-41.
121. Goldberg GS,Martyn KD,Lau AF.A connexin 43 antisense vector reduces the ability of normal cells to inhibit the foci formation of transformed cells.Mol Carcinog. 1994;11:106-14.
122. Yamasaki H.Aberrant expression and function of gap junctions during carcinogenesis.Environ Health Perspect. 1991;93:191-7.
123. Laird DW,Fistouris P,Batist G, et al.Deficiency of connexin43 gap junctions is an independent marker for breast tumors.Cancer Res. 1999;59:4104-10.
124. Martin W,Zempel G,Hulser D,Willecke K.Growth inhibition of oncogene-transformed rat fibroblasts by cocultured normal cells: relevance of metabolic cooperation mediated by gap junctions.Cancer Res. 1991;51:5348-51.
125. Zhang W,Couldwell WT,Simard MF,Song H,Lin JH,Nedergaard M.Direct gap junction communication between malignant glioma cells and astrocytes.Cancer Res. 1999;59:1994-2003.
126. Valiunas V,Bechberger JF,Naus CC,Brink PR,Goldberg GS.Nontransformed cells can normalize gap junctional communication with transformed cells.Biochem Biophys Res Commun. 2005;333:174-9.
127. Shen Y,Chen CS,Ichikawa H,Goldberg GS.SRC induces podoplanin expression to promote cell migration.J Biol Chem. 2010;285:9649-56.
128. Friedl P,Wolf K.Tumour-cell invasion and migration: diversity and escape mechanisms.Nat Rev Cancer. 2003;3:362-74.
129. Hanahan D,Weinberg RA.Hallmarks of cancer: the next generation.Cell. 2011;144:646-74.
130. Ding L,Wang Z,Yan J, et al.Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway.J Clin Invest. 2009;119:349-61.
131. Lin J,Ding L,Jin R, et al.Four and a half LIM domains 1 (FHL1) and receptor interacting protein of 140kDa (RIP140) interact and cooperate in estrogen signaling.Int J Biochem Cell Biol. 2009;41:1613-8.
132. Li X,Jia Z,Shen Y, et al.Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate.Cancer Sci. 2008;99:1326-33.
133. Sakashita K,Mimori K,Tanaka F, et al.Clinical significance of loss of Fhl1 expression in human gastric cancer.Ann Surg Oncol. 2008;15:2293-300.
134. Ding L,Niu C,Zheng Y, et al.FHL1 interacts with oestrogen receptors and regulates breast cancer cell growth.J Cell Mol Med. 2011;15:72-85.
135. Niu C,Liang C,Guo J, et al.Downregulation and growth inhibitory role of FHL1 in lung cancer.Int J Cancer. 2012;130:2549-56.
136. Ruan K,Fang X,Ouyang G.MicroRNAs: novel regulators in the hallmarks of human cancer.Cancer Lett. 2009;285:116-26.
137. Caldas C,Brenton JD.Sizing up miRNAs as cancer genes.Nat Med. 2005;11:712-4.
138. Crawford M,Brawner E,Batte K, et al.MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines.Biochem Biophys Res Commun. 2008;373:607-12.
139. Wang Y,Toh HC,Chow P, et al.MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms.FASEB J. 2012;26:3032-41.
140. Li X,Shen Y,Ichikawa H,Antes T,Goldberg GS.Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration.Oncogene. 2009;28:4272-83.
141. Klemke RL,Leng J,Molander R,Brooks PC,Vuori K,Cheresh DA.CAS/Crk coupling serves as a "molecular switch" for induction of cell migration.J Cell Biol. 1998;140:961-72.
142. Sriram G,Birge RB.Emerging roles for crk in human cancer.Genes Cancer. 2010;1:1132-9.
143. Oneyama C,Ikeda J,Okuzaki D, et al.MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.Oncogene. 2011;30:3489-501.
144. Oneyama C,Morii E,Okuzaki D, et al.MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression.Oncogene. 2012;31:1623-35.
145. NCBI. 2006; Available from: http://www.ncbi.nlm.nih.gov/geo/gds/profileGraph.cgi?&dataset=AAPBCEC1OzPiix&dataset=JGhQT_Qphthrrt$&gmin=31.552600&gmax=519.480000&absc=&uid=18849462&gds=1732&idref=1552626_a_at&sannot=TMEM163.
146. Brune V,Tiacci E,Pfeil I, et al.Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis.J Exp Med. 2008;205:2251-68.
147. Holmes K,Roberts OL,Thomas AM,Cross MJ.Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition.Cell Signal. 2007;19:2003-12.
148. Hicklin DJ,Ellis LM.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.J Clin Oncol. 2005;23:1011-27.
149. Ferrara N,Hillan KJ,Novotny W.Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.Biochem Biophys Res Commun. 2005;333:328-35.
150. Holash J,Davis S,Papadopoulos N, et al.VEGF-Trap: a VEGF blocker with potent antitumor effects.Proc Natl Acad Sci U S A. 2002;99:11393-8.
151. Roskoski R.Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.Biochem Biophys Res Commun. 2007;356:323-8.
152. Wicki A,Christofori G.The potential role of podoplanin in tumour invasion.Br J Cancer. 2007;96:1-5.
153. Navarro A,Perez RE,Rezaiekhaligh MH,Mabry SM,Ekekezie. Polarized migration of lymphatic endothelial cells is critically dependent on podoplanin regulation of Cdc42.Am J Physiol Lung Cell Mol Physiol. 2011;300:L32-42.
154. Martin-Villar E,Megias D,Castel S,Yurrita MM,Vilaro S,Quintanilla M.Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition.J Cell Sci. 2006;119:4541-53.
155. Nose K,Saito H,Kuroki T.Isolation of a gene sequence induced later by tumor-promoting 12-O-tetradecanoylphorbol-13-acetate in mouse osteoblastic cells (MC3T3-E1) and expressed constitutively in ras-transformed cells.Cell Growth Differ. 1990;1:511-8.
156. Gandarillas A,Scholl FG,Benito N,Gamallo C,Quintanilla M.Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis.Mol Carcinog. 1997;20:10-8.
157. Villar E,Scholl F,Amat C,Ávila M.PA2.26 antigen (T1α/podoplanin): a small mucin-like transmembrane glycoprotein associated with cell migration and cancer.Clin Transl Oncol. 2003;5:491-9.
158. Wicki A,Lehembre F,Wick N,Hantusch B,Kerjaschki D,Christofori G.Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton.Cancer Cell. 2006;9:261-72.
159. Kono T,Shimoda M,Takahashi M, et al.Immunohistochemical detection of the lymphatic marker podoplanin in diverse types of human cancer cells using a novel antibody.Int J Oncol. 2007;31:501-8.
160. Kawaguchi H,El-Naggar AK,Papadimitrakopoulou V, et al.Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.J Clin Oncol. 2008;26:354-60.
161. Yuan P,Temam S,El-Naggar A, et al.Overexpression of podoplanin in oral cancer and its association with poor clinical outcome.Cancer. 2006;107:563-9.
162. Schacht V,Dadras SS,Johnson LA,Jackson DG,Hong YK,Detmar M.Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors.Am J Pathol. 2005;166:913-21.
163. Liang H,Wu H,Giorgadze TA, et al.Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to skin.Am J Surg Pathol. 2007;31:304-10.
164. Kato Y,Kaneko MK,Kunita A, et al.Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.Cancer Sci. 2008;99:54-61.
165. Nakazawa Y,Sato S,Naito M, et al.Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis.Blood. 2008;112:1730-9.
166. Ochoa-Alvarez JA,Krishnan H,Shen Y, et al.Plant lectin can target receptors containing sialic acid, exemplified by podoplanin, to inhibit transformed cell growth and migration.PLoS One. 2012;7:e41845.
167. Puls LN,Eadens M,Messersmith W.Current status of SRC inhibitors in solid tumor malignancies.Oncologist. 2011;16:566-78.
168. Gratacap MP,Martin V,Valera MC, et al.The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.Blood. 2009;114:1884-92.